The Current Status of Neoadjuvant Therapy in HER2-Positive Breast Cancer.

Slides:



Advertisements
Similar presentations
Miles D et al. Proc SABCS 2012;Abstract P
Advertisements

Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in HER2- Positive, First-Line Metastatic Breast Cancer (MBC) Baselga.
Metastatic HER2-Positive Breast Cancer: Treatment Selection and Sequencing in the First Line and Beyond Moderator: Joseph Gligorov, MD, PhD Head, Cancer.
William J. Gradishar MD, FACP Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley Center For Women's Cancer Care Robert H. Lurie Comprehensive.
Updates from the San Antonio Breast Cancer Symposium 2013 HER2+ Breast Cancer Julie R. Gralow, M.D. Director and Jill Bennett Professor of Breast Medical.
Gianni L et al. Proc SABCS 2012;Abstract GS6-7.
Assistant Professor of Medicine Dana-Farber Cancer Institute
Terapia Neoadiuvante Revisione delle evidenze scientifiche
Lapatinib versus Trastuzumab in Combination with Neoadjuvant Anthracycline-Taxane-Based Chemotherapy: Primary Efficacy Endpoint Analysis of the GEPARQUINTO.
Cortés J et al. ASCO 2009; Abstract (Poster Discussion)
Baselga J et al. Proc SABCS 2010;Abstract S3-3.
HERA TRIAL: 2 Years versus 1 Year of Trastuzumab After Adjuvant Chemotherapy in Women with HER2-Positive Early Breast Cancer at 8 Years of Median Follow-Up.
Neoadjuvant Target Therapy in Her-2 Positive Breast Cancer Dr. Khaled Abulkhair, PhD Medical Oncology SCE, Royal College, UK Ass. Professor of Clinical.
Responses to Subsequent Anti-HER2 Therapy After Treatment with Trastuzumab-DM1 in Women with HER2- Positive Metastatic Breast Cancer 1 A Phase Ib/II Trial.
Mothaffar F. Rimawi, Ingrid A. Mayer, Andres Forero, Rita Nanda, Matthew P. Goetz, Angel A. Rodriguez, Anne C. Pavlick, Tao Wang, Susan G. Hilsenbeck,
CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 KRISTINE: Neoadjuvant T-DM1 + Pertuzumab vs Chemotherapy With Trastuzumab.
Volume 34, Pages (August 2017) Palliative systemic therapy and overall survival of 1,395 patients with advanced breast cancer – Results from the.
Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB (HER2-Positive) and CALGB.
A. Schema of NSABP B-27 trial comparing neoadjuvant AC to neoadjuvant AC followed by neoadjuvant docetaxel and to neoadjuvant AC followed by adjuvant docetaxel.
Neoadjuvant Therapy for HER2+ Disease
HER2 inhibition: when more is better?
TRAIN-2 (BOOG ): Phase III Trial of Neoadjuvant Chemotherapy ± Anthracyclines With Dual HER2 Blockade in HER2+ EBC CCO Independent Conference Highlights*
CCO Independent Conference Highlights
A Single-Arm Phase IIIb Study of Pertuzumab and Trastuzumab with a Taxane as First-Line Therapy for Patients with HER2-Positive Advanced Breast Cancer.
Evolving Standards in HER2-Targeted Adjuvant Therapy for Breast Cancer
Presented By Mette Van Ramshorst at 2017 ASCO Annual Meeting
Blackwell KL et al. SABCS 2009;Abstract 61
CCO Independent Conference Highlights
Swain SM et al. Proc SABCS 2012;Abstract P
New Paradigms for HER2-Positive Early Breast Cancer: Implications and Application.
Metastatic HER2+ Breast Cancer: Resistance
CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer: Implementing Paradigms in Clinical Practice.
Neoadjuvant Therapy for HER2-Positive Breast Cancer
Perspectives on Triple-Negative Breast Cancer
Updates on the Use of Adjuvant Therapy in HER2-Positive Breast Cancer
Her2-positive breast cancer: updating current best practice
سرطان الثدي Breast Cancer
Overall Program Goals. Overall Program Goals Current Approaches.
Program Goals. Implementing the Updated American Thyroid Association Guidelines and Recommendations for RAI-R DTC.
The Nurse View: Best Practices in Advanced Non-Small Cell Lung Cancer
PARP and Other DNA Damage Repair Inhibitors in Solid Tumors: An Update
HER2+ breast cancer: from RCT to the real world scenario
Neoadjuvant Therapy in HER2-Positive Breast Cancer
Activity Goals. Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?
PARP Inhibitors and Cancer: What Do You Need to Know?
Krop I et al. SABCS 2009;Abstract 5090.
Best Practices in Metastatic Colorectal Cancer
Managing gBRCA-Positive Metastatic Breast Cancer
Adjuvant Dose-Dense Chemotherapy in Breast Cancer: Standard of Care in High-Risk Patients Breast Care 2016;11: DOI: / Fig. 1. Strategies.
Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: First-line Considerations.
Untch M et al. Proc SABCS 2010;Abstract P
Antithrombotic Protection in CAD and HF
Reviewer: Dr. Sunil Verma Date posted: December 12th, 2011
Program Goals. Single vs Dual HER2 Blockade for Metastatic HER2-Positive Breast Cancer.
Optimizing Neoadjuvant Treatment for Primary Breast Cancer
Program Goals. Implementing the Updated American Thyroid Association Guidelines and Recommendations for RAI-R DTC.
Essential Concepts in the Use of Immunotherapies in Bladder Cancer
The Road to Quality Improvement in HER2-Positive Breast Cancer
Hormone Receptor-Positive Advanced Breast Cancer Introduction
Advances in Gastrointestinal Cancers
Treatment of Locally Advanced Pancreatic Cancer
Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: Considerations for Previously Treated Disease.
Current Challenges in Managing Hemophilia
Preparing for Checkpoint Inhibitors in Breast Cancer
Quality Improvement and Molecular Profiling in Advanced Non-Small Cell Lung Cancer.
Navigating New Treatment Landscapes in HR+ HER2-Negative Advanced Breast Cancer.
Prostacyclin Pathway Agents in Action
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Moving Care Forward in Advanced Gastric Cancer
Maximizing Disease-Free Survival in Early-Stage HER2-Positive Breast Cancer.
Presentation transcript:

The Current Status of Neoadjuvant Therapy in HER2-Positive Breast Cancer

Program Goals

Neoadjuvant Chemotherapy: Historical Context

pCR

Goals of Modern Neoadjuvant Therapy

Eligibility for Neoadjuvant Approach

Case 1

Case 1 (cont)

NeoSphere Trial 2015 Update

Other Pertuzumab + Trastuzumab Trials

Dual Blockade of HER2 With Lapatinib + Trastuzumab

Adverse Effects of Neoadjuvant Regimens for HER2-Positive Breast Cancer

Case 1 (After Neoadjuvant Regimen)

Case 2: Alternatives to Dual HER2 Blockade and Chemotherapy

MARIANNE Update: 2015

Summary: Neoadjuvant HER2-Directed Therapy

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.